Orion Research Foundation grants EUR 1,112,000 for research in 2024
Orion Research Foundation grants EUR 1,112,000 for research in 2024
Press release 15 November, 2023 at 9.00 EET
Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024. Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research and max EUR 6,000 for 95 young researchers for doctoral dissertation work. One of the postdoctoral grants was distributed from Maritza and Reino Salonen’s Fund which is administered by Orion Research Foundation.
Orion Research Foundation sr is annually distributing its return on investment and donations from Orion Corporation as grants for young researchers for doctoral dissertation work and postdoctoral research. In the last few years the Research Foundation has been distributing annual grants based on applications for the total sum of MEUR 1 for research in medicine, veterinary medicine, pharmacy and related sciences, such as chemistry and physics.
Grants for 2024
Grants for postdoctoral research, 20,000 – 50,000 euros
He Liye, Postdoctoral researcher, Helsingin yliopisto, Identifying multi-omics biomarker panels for prediction of treatment responses of patients with chronic lymphocytic leukemia (CLL) using machine learning models, 30,000 €
Hossain Iftakher, Senior Post-doctoral Clinical Researcher, Neurocenter, Turku University Hospital, Turun yliopisto, Uudet verestä mitattavat biomerkkiaineet akuutin diffuusin aksonivaurion saaneiden ja pitkäaikaisista jälkioireista kärsivien potilaiden tunnistamisessa, 30,000 €
Ignatenko Olesia, Biological sciences, Helsingin yliopisto, Defining neuronal mechanisms that control circulating lipoprotein levels and liver lipid content, 30,000 €
Kaivola Karri Kasperi, LT, National Institutes of Health, Lewyn kappale -patologian kertymisen ja etenemisen säätelymekanismit, 50,000 €
Kivioja (née Karjalainen) Riikka Johanna, FT, Baselin Yliopistollinen sairaala, Basel, Sveitsi, Functional analysis of hematopoietic stem cells carrying CALR mutations in models of myeloproliferative neoplasms, 20,000 €
Kuitunen Ilari Matti Eemeli, Dosentti, LT, Itä-Suomen yliopisto Kuopion kampus, Näyttöön perustuvaa hoitoa lasten yleisiin infektiotauteihin, 30,000 €
Kuusanmäki Heikki Aleksi, PhD, Helsingin yliopisto, Targeting drug resistance in TP53-mutated acute myeloid leukemia, 35,000 €
Niemelä Tytti Maaria, FM, ELT, hevossairauksien erikoiseläinlääkäri, Helsingin yliopisto, Kliinisen hevos- ja pieneläinlääketieteen osasto, Changes in prevalence of extracellular vesicles and fatty acid profile of synovial fluid and clinical signs of osteoarthritis following intra-articular platelet-rich plasma treatment in horses: a controlled clinical trial, 35,000 €
Nikkola Jussi Mikael, Lääketieteen tohtori, Tampereen yliopisto, Randomized Clinical Trials Evaluating Urine DNA Testing as a Substitute for Cystoscopy in Urothelial Carcinoma Diagnostics and Surveillance, 40,000 €
Puris Elena, Provisor, Itä-Suomen yliopisto Kuopion kampus, A.I. Virtanen Institute for Molecular Sciences, Unravelling the effects of tau pathology on neurovascular transporter protein expression in Alzheimer's disease, 35,000 €
Räisänen Laura Karelia, Lääketieteen tohtori, Tampereen yliopisto, Evaluating the role of oral vancomycin in the treatment of the colitis associated with PSC- Ulcerative Colitis (PSC-UC) by correlating disease phenotype and treatment responses to changes in the gut microbiota composition, 50,000 €
San Martin Galindo Paola, Helsingin yliopisto, Uncovering mechanisms of new compounds for persistent infections - a novel approach for discovering bacterial ligands, 35,000 €
Taavitsainen Sinja Julia, Filosofian tohtori, Karoliininen instituutti, Sensitive detection of circulating tumor DNA fraction dynamics and evaluation of its clinical utility in metastatic castration-resistant prostate cancer, 40,000 €
van der Kolk Bertine Willemina (Birgitta), Researcher, Helsingin yliopisto, Obesity and aging: effects on adipose tissue mitochondria, inflammation, and insulin resistance in monozygotic twin pairs discordant for BMI, 30,000 €
Virtanen Jenni Maaret Elina, Filosofian maisteri, Helsingin yliopisto, Ortho- ja parapoxvirusten diagnostiikka, leviäminen ja monimuotoisuus, 30,000 €
Virtanen Jussi Eemil Iisakki, LT, korva-, nenä- ja kurkkutautien erikoislääkäri, Tampereen yliopisto, In vitro modeling of human respiratory and olfactory epithelium to understand olfactory pathophysiology, 40,000 €
Maritza and Reino Salonen’s fund
Björnholm Lassi, Lääketieteen tohtori, filosofian maisteri, Oulun yliopisto, Kliinisen lääketieteen tutkimusyksikkö, Prenatal maternal predictors of brain structural development, 30,000 €
Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research. These grants are in total EUR 590,000.
Grants for doctoral dissertation work, 3,000 – 6,000 euros
In addition, Orion Research Foundation has awarded EUR 3,000 – 6,000 for 95 researchers for doctoral dissertation work. These grants are in total EUR 522,000.
Orion Research Foundation sr
For further information:
Anu Imppola
Manager, Orion Research Foundation sr
Puh: +358 (0)10 426 3803
anu.imppola(at)orion.fi
Publisher
Orion Research Foundation sr
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu
Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding
September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202
Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release
September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th
Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse
Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er
Registration of share capital increase in IDEX Biometrics 1 Dec 20231.12.2023 17:30:00 CET | Press release
Reference is made to the notice on 21 November 2023 regarding employees having exercised 389,608 incentive subscription rights at NOK 0.15 per share. The capital increase has been registered and the shares will be delivered soonest. Following the issue, the company's share capital is NOK 209,551,597.20 divided into 1,397,010,648 shares, each with a nominal value of NOK 0.15. For further information contact: Marianne Bøe, Investor Relations E-mail: marianne.boe@idexbiometrics.com Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As